Skip to main content
. 2019 Mar 21;7(5):716–722. doi: 10.1177/2050640619839918

Table 1.

Patient characteristics at first fecal microbiota transfer (FMT).

Number of patients – no. 256
Age – years
 Median (IQR) 75 (63–81)
Female – no. (%) 157 (61.3)
BMI
 Median (range) 22.6 (14.87–54.82)
ECOG performance score – value
 Median (IQR) 3 (1–4)
Comorbidities – no. (%)
 Cardiovascular 154 (60.2)
 Gastrointestinal (except CDI) 90 (35.2)
 Endocrinological 81 (31.6)
 Nephrological 75 (29.3)
 Hematological/oncological 68 (26.6)
 Pulmonary 52 (20.3)
 Neurological 37 (14.5)
 Psychiatric 34 (13.3)
 Orthopedic 23 (9.0)
 Rheumatological 15 (5.9)
 Urological 10 (3.9)
 Othera 28 (10.9)
 None 12 (4.7)
Transplantation – no. (%)
 Solid organ 8 (3.1)
 Allogenic stem cell 4 (1.6)
Immunosuppression – no. (%)
 Chemotherapy 18 (7.0)
 Other immunosuppressive medication 48 (18.8)
CDI recurrences before FMT – no.
 Median (IQR) 3 (2–4)
 Antibiotic pre-treatmentb – no. (%) 237 (92.6)
 Sequential Metro+Vanco 91 (35.5)
 Sequential Metro+Vanco+Fidaxo 72 (28.1)
 Vancomycin only 31 (12.1)
 Sequential Fidaxo+Vanco 16 (6.3)
 Sequential Metro+Vanco+Rifax 11 (4.3)
 Otherc 16 (6.3)
 Unknown 19 (7.4)

BMI = body mass index; CDI = Clostridioides difficile infection; ECOG = Eastern Cooperative Oncology Group (range 0–5); IQR = interquartile range; SD = standard deviation.

a

Other: dermatological n = 5 (2.0%), ophthalmological n = 5 (2.0%), immunosuppressive n = 6 (2.3%), infective n = 4 (1.6%), coagulative n = 3 (1.2%), gynecological n = 4 (1.6%), otorhinolaryngological n = 1 (0.4%).

b

Antibiotic pre-treatment: any kind of antibiotic ever given to the patient during previous CDI episodes

c

Other: metronidazole only n = 7, sequential metronidazole + vancomycin + fidaxomicin + rifaximin n = 3, fidaxomicin only n = 2, sequential rifaximin + vancomycin n = 1, sequential metronidazole + vancomycin + fidaxomicin + rifaximin + tigecycline n = 1, drug sequence unknown n = 2.